EFNB2 and head and neck squamous cell carcinoma: The progression-free interval showed a similar pattern in the high EPHB4-low EFNB2 vs. low EPHB4-high EFNB2 cohort (Hazard ratio: 0.5961; CI: 0.3910–0.9089; p-value: 0.0158) (Fig. 9d) suggesting that high EPHB4 and low EFNB2 can be used as a correlate for survival outcomes in HNSCC patients.